AZ agrees Seroquel product liability claims in principle
Agreements in principle are subject to agreement on non-monetary terms
AstraZeneca has reached agreements in principle on monetary terms with attorneys representing approximately 17,500 Seroquel product liability claimants in the US for approximately US$198m (€149m). The agreements in principle are subject to agreement on non-monetary terms.
The specific terms of the agreements, which are the result of court-ordered mediation, are confidential. AstraZeneca continues to participate in the mediation process covering claims in both federal and state jurisdictions.
As of June 29, approximately 2,900 additional cases have been dismissed by order or agreement and approximately 1,825 of those cases have been dismissed with prejudice. The only jury trial to date resulted in a defense verdict in favour of AstraZeneca.